Skip to main content
NAVCO Pharmaceuticals logo

NAVCO Pharmaceuticals — Investor Relations & Filings

Ticker · NAV ISIN · CA63942R1091 LEI · 8945003WKDH61M8UB963 TSXV Manufacturing
Open in API
Filings indexed 199 across all filing types
Latest filing 2025-03-28 Audit Report / Informat…
Country CA Canada
Listing TSXV NAV

About NAVCO Pharmaceuticals

https://www.navcopharma.com/

NAVCO Pharmaceuticals is a biotechnology company specializing in the research, development, and commercialization of nanotechnology products and materials. The company utilizes proprietary Computerized Nano-meter Algorithms to create innovative solutions for anti-viral, anti-fungal, and anti-bacterial treatments. NAVCO focuses on developing supplemental and therapeutic consumer health and wellness products. A key offering is the BioActive™ line, which includes non-toxic, non-flammable, and alcohol-free hand cleansers, creams, and surface disinfectants designed to provide extended protection against germs and microorganisms. These nanotechnology products are marketed across various sectors, including medicine and textiles, providing next-generation protection solutions for multiple industries.

Recent filings

Filing Released Lang Actions
Notice of the meeting and record date - English.pdf
Audit Report / Information Classification · 100% confidence The document is titled 'INDEPENDENT AUDITOR’S REPORT' and contains an auditor's opinion on the consolidated financial statements of Lake Louise Limited Partnership for the years ended November 30, 2024 and 2023. It includes detailed audit procedures, key audit matters, management responsibilities, and the auditor's responsibilities. The document also contains the consolidated financial statements themselves, including balance sheets, statements of net income, statements of cash flows, and notes to the consolidated financial statements. The presence of the full audited financial statements and the auditor's report indicates this is a standalone audit report rather than a full annual report or just an announcement. The document length is substantial (15,000 characters), and it contains substantive financial data and analysis. Therefore, the document fits the definition of an Audit Report / Information (AR). FY 2024
2025-03-28 English
Notice of the meeting and record date - English.pdf
Regulatory Filings Classification · 80% confidence The document is a regulatory filing via SEDAR+ notifying exchanges and securities administrators of the Issuer’s upcoming Annual General Meeting date and record date information. It does not contain AGM presentations/materials (AGM-R), proxy solicitation detail (PSI), an actual report (10-K/IR), dividend notice (DIV), or other specific categories. It is a general regulatory announcement, so it falls under the fallback “Regulatory Filings” category (RNS).
2025-03-28 English
Interim MD&A - English.pdf
Management Reports Classification · 95% confidence The document is titled “Management Discussion & Analysis” for the quarter ended December 31, 2024, contains management’s detailed commentary on results of operations, liquidity, capital resources, off‐balance sheet arrangements, related party transactions, and financial risk disclosures. This matches the definition of a Management Report (MDA), which is management’s detailed explanation of financial results and business trends. It is not a full interim financial statement package but rather specifically the MD&A section, fitting precisely into the MDA category.
2025-03-03 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 78% confidence The document is a certification under Form 52-109FV2 (Venture Issuer Basic Certificate) whereby the CEO certifies the interim financial report and interim MD&A. It is not itself the interim report (IR) nor an announcement of its publication, nor an audit opinion. It is a regulatory certificate filing under NI 52-109 and does not fit any specific category like IR, AR, or MDA. Therefore, it falls under the fallback category Regulatory Filings (RNS).
2025-03-03 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 40% confidence The document is a Form 52-109FV2 “Venture Issuer Basic Certificate” under Canadian NI 52-109, which certifies the issuer’s interim financial report and interim MD&A for the period ended December 31, 2024. It is a regulatory certification rather than the interim report itself. There is no dedicated category for certification forms, so it falls into the general regulatory filings fallback category.
2025-03-03 English
Interim financial statements/report – English.pdf
Board/Management Information Classification · 92% confidence The document is an immediate report filed with the Israeli Securities Authority announcing that a senior executive (the Chairman of the Board) has ceased to hold office. This clearly falls under announcements of changes in board or senior management positions, matching the Board/Management Information category.
2025-03-03 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.